Universal Beteiligungs und Servicegesellschaft mbH Invests $906,000 in InMode Ltd. (NASDAQ:INMD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a new stake in InMode Ltd., purchasing 51,054 shares valued at approximately $906,000.
• A total of 68.04% of InMode's stock is held by institutional investors and hedge funds, indicating strong institutional interest in the company.
• InMode's stock has shown fluctuations, currently priced at $13.74, with a one-year trading range between $13.14 and $19.85.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of InMode Ltd. (NASDAQ:INMD - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 51,054 shares of the healthcare company's stock, valued at approximately $906,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.07% of InMode at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. CWM LLC increased its holdings in InMode by 106.4% during the 1st quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock worth $42,000 after acquiring an additional 1,221 shares during the period. Orion Capital Management LLC bought a new position in shares of InMode in the 4th quarter worth $65,000. Covestor Ltd increased its holdings in shares of InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after buying an additional 723 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of InMode by 6,128.7% in the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock worth $105,000 after buying an additional 6,190 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of InMode in the 4th quarter worth $114,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Price Performance

INMD traded up $0.20 during trading on Monday, hitting $13.94. 786,726 shares of the stock traded hands, compared to its average volume of 1,291,686. The firm has a market capitalization of $880.83 million, a P/E ratio of 5.65 and a beta of 1.93. The firm has a 50-day moving average of $14.33 and a 200 day moving average of $15.96. InMode Ltd. has a 12-month low of $13.14 and a 12-month high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The healthcare company reported $0.47 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.03). The firm had revenue of $95.60 million for the quarter, compared to analysts' expectations of $98.45 million. InMode had a net margin of 44.50% and a return on equity of 18.38%. The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.34 EPS. As a group, equities analysts predict that InMode Ltd. will post 1.75 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on INMD shares. Needham & Company LLC reissued a "hold" rating on shares of InMode in a report on Wednesday, July 30th. Jefferies Financial Group decreased their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a report on Monday, April 14th. UBS Group decreased their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. BTIG Research lowered shares of InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group reissued a "hold" rating and issued a $15.00 price target on shares of InMode in a report on Friday, July 11th. Seven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $18.04.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.